Hasta un 35% de sobreprecio habría pagado la Central de Abastecimiento del Sistema Nacional de Servicios de Salud (Cenabast), que intermedia la compra de medicamentos para consultorios y hospitales públicos. Ese fue uno de los puntos medulares del requerimiento de la Fiscalía Nacional Económica (FNE) en contra de los laboratorios Fresenius Kabi Chile, su filial Sanderson, y Biosano, por acordar un supuesto pacto para afectar el resultado de los concursos convocados entre 1999 y la primera mitad de 2013.
Featured News
White House Prepares Overhaul of U.S. Cyber Rules
Dec 16, 2025 by
CPI
DirecTV Wins Second Chance in Antitrust Case Against Nexstar
Dec 16, 2025 by
CPI
Democrats Call for Tough Review of Nexstar-Tegna Merger
Dec 16, 2025 by
CPI
US FTC and States Expand Suit Accusing Uber of Deceptive Subscription Practices
Dec 16, 2025 by
CPI
US Hits Pause on Implementing UK Trade Deal Amid Disagreement on Digital Regs
Dec 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi